CN115362155B - 芳胺类衍生物及其制备方法和医药用途 - Google Patents

芳胺类衍生物及其制备方法和医药用途 Download PDF

Info

Publication number
CN115362155B
CN115362155B CN202180025028.9A CN202180025028A CN115362155B CN 115362155 B CN115362155 B CN 115362155B CN 202180025028 A CN202180025028 A CN 202180025028A CN 115362155 B CN115362155 B CN 115362155B
Authority
CN
China
Prior art keywords
compound
amino
mmol
reaction
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180025028.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115362155A (zh
Inventor
殷惠军
闫旭
田卫学
陈士柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN115362155A publication Critical patent/CN115362155A/zh
Application granted granted Critical
Publication of CN115362155B publication Critical patent/CN115362155B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180025028.9A 2020-07-22 2021-07-21 芳胺类衍生物及其制备方法和医药用途 Active CN115362155B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020107106924 2020-07-22
CN202010710692 2020-07-22
PCT/CN2021/107569 WO2022017408A1 (fr) 2020-07-22 2021-07-21 Dérivé d'arylamine, son procédé de préparation et son utilisation médicale

Publications (2)

Publication Number Publication Date
CN115362155A CN115362155A (zh) 2022-11-18
CN115362155B true CN115362155B (zh) 2024-06-18

Family

ID=79728497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025028.9A Active CN115362155B (zh) 2020-07-22 2021-07-21 芳胺类衍生物及其制备方法和医药用途

Country Status (2)

Country Link
CN (1) CN115362155B (fr)
WO (1) WO2022017408A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146205A4 (fr) 2020-05-05 2024-05-29 Nuvalent, Inc. Agents chimiothérapeutiques à base d'éther macrocyclique hétéroaromatique
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111426A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
CN110914258A (zh) * 2017-07-14 2020-03-24 先天肿瘤免疫公司 Nlrp3调节剂
WO2020150116A1 (fr) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Modulateurs de nlrp3
WO2020150114A1 (fr) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Modulateurs hétérocycliques de nlrp3, destinés à être utilisés dans le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809357B (zh) * 2003-06-20 2010-12-22 科勒制药有限公司 小分子Toll样受体(TLR)拮抗剂
US9670205B2 (en) * 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3337481B1 (fr) * 2015-08-21 2020-11-11 The University of Kansas Dérivés de quinoline-2-amine en tant qu'agonistes sélectifs du tlr8 humaine pour augmenter la réponse immunitaire
AU2017318601B2 (en) * 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111426A (zh) * 2017-06-23 2019-01-01 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
CN110914258A (zh) * 2017-07-14 2020-03-24 先天肿瘤免疫公司 Nlrp3调节剂
WO2020150116A1 (fr) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Modulateurs de nlrp3
WO2020150114A1 (fr) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Modulateurs hétérocycliques de nlrp3, destinés à être utilisés dans le traitement du cancer
CN113286787A (zh) * 2019-01-14 2021-08-20 先天肿瘤免疫公司 Nlrp3调节剂
CN113301962A (zh) * 2019-01-14 2021-08-24 先天肿瘤免疫公司 用于治疗癌症的杂环nlrp3调节剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
876134-50-8 et al.STN,REGISTRY，876134-50-8 et al.STN,REGISTRY.2006, *
Developing Inhibitors of the p47phox−p22phox Protein−Protein Interaction by Fragment-Based Drug Discovery;Sara Marie Øie Solbak et al.;J. Med. Chem.;第63卷;第1156-1177页 *
RN 2261038-37-1，RN 2261038-36-0，RN 2261038-33-7，RN 858467-97-7，RN 857759-54-7，RN 123373-42-2.STN-REGISTRY.2019, *
RN 2498561-53-6.STN-REGISTRY.2020, *

Also Published As

Publication number Publication date
CN115362155A (zh) 2022-11-18
WO2022017408A1 (fr) 2022-01-27

Similar Documents

Publication Publication Date Title
KR102426043B1 (ko) 액티빈 수용체 유사 키나아제의 저해제
CN113637005A (zh) 用于癌症治疗的kras抑制剂
CN109422755B (zh) 一种含氮杂环化合物、制备方法、中间体、组合物和应用
JP6431593B2 (ja) ピリジニルアミノピリミジン誘導体、その製造方法、および用途
JP2022517723A (ja) Ｃｄｋ阻害剤としての大環状化合物、その製造方法及びその医薬品における応用
CN112654622B (zh) 并环化合物、其制备方法及用途
CN105503827B (zh) Egfr抑制剂及其制备方法和用途
CN115362155B (zh) 芳胺类衍生物及其制备方法和医药用途
CN113195469B (zh) 含氮并环化合物、其制备方法及用途
CN110072865B (zh) 吡咯并芳杂环类化合物及其制备方法和医药用途
IL311024A (en) Substituted tricyclic compounds as parp inhibitors and use thereof
KR20200115583A (ko) Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도
KR20190017959A (ko) TGF-βRI 억제제인 벤조트리아졸에서 유도된 α,β-불포화 아미드계 화합물
JP2023145547A (ja) Ｃｄ７３阻害剤、その製造方法と応用
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
WO2022135590A1 (fr) Composés pyrimido-hétérocycliques, et leur procédé de préparation et leur utilisation
JP7041821B2 (ja) アミノ置換窒素含有縮合環化合物、その調製方法及び使用
CN116472047B (zh) 芳胺类衍生物及其制备方法和医药用途
CN113754682A (zh) 具有大环结构的化合物及其用途
CA3243206A1 (fr) Bioinhibiteur contenant du propylène cétone, son procédé de préparation et son utilisation
AU2021282039A1 (en) Arylformamide compound and preparation method and medical use thereof
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN117813308A (zh) 含氮稠环类化合物及其制备方法和医药用途
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant